Tumor necrosis factor (TNF) is a pleiotropic cytokine involved in the regulation of numerous physiological and pathological processes such as inflammation, cancer, autoimmunity and infection. TNF is also linked to the development of various neurological disorders, including multiple sclerosis (MS). TNF exists in two biologically active forms, transmembrane (tmTNF) and soluble (solTNF), whose functions are mediated by TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). By virtue of their different binding affinities, solTNF is the primary signaling partner of TNFR1, while tmTNF preferentially signals through TNFR2. The cellular processes activated by the two receptors are often opposite: TNFR1 mediates apoptosis and chronic inflammation, TNFR2 mediates cell survival, resolution of inflammation, immunity and myelination. Numerous studies have underscored the importance of distinguishing between the functions of solTNF and tmTNF, and have associated MS and its animal model experimental autoimmune encephalomyelitis (EAE) to the detrimental effects of solTNF and TNFR1. In our own studies we have demonstrated not only that solTNF is detrimental, but that tmTNF is protective and important for repair and remyelination in EAE. We showed that mice treated with the biologic XPro1595, a dominant negative TNF that selectively blocks solTNF without affecting tmTNF, recover from EAE-induced paralysis. This is associated with neuroprotection, improved myelin integrity and increased remyelination. How does this occur? Our HYPOTHESIS is that selective inhibition of solTNF causes a shift in the balance of TNF receptor activation towards TNFR2. This leads to the downstream activation of TNFR2-dependent cascades which carry out the protective functions of tmTNF in EAE. Since in the CNS TNFR2 is expressed in oligodendrocytes, oligodendrocyte precursors, astrocytes and microglia, all these cell populations could potentially be the effectors of tmTNF beneficial effect. In this proposal we will focus exclusively on microglia. We have found that TNFR2 is expressed in microglia, both in mouse EAE and in MS. Activation of TNFR2 in microglia has been shown to induce the production of anti-inflammatory and neuroprotective mediators. On this basis, we hypothesize that activation of TNFR2 in microglia by tmTNF sets off protective signaling cascades that contribute to tmTNF beneficial effects. The OBJECTIVE of our studies is to determine whether microglial TNFR2 is a mediator of tmTNF protective function in EAE. We will address this question with an innovative genetic approach consisting of a new mouse model generated in our laboratory where TNFR2 is ablated from the myeloid population (LysMcreTNFR2fl/fl mice) to obtain bone-marrow chimeras that will allow for specific investigation of microglial TNFR2. These experiments will shed light on tmTNF-TNFR2 signaling in microglia in vivo, a question that has not been addressed to date. We believe our studies will significantly advance the current knowledge on the role of tmTNF and TNFR2 in EAE, providing the basis for the possible development of a selective solTNF inhibitor as a new therapy for MS.

Public Health Relevance

Multiple sclerosis (MS) is the most common neurological disease among young adults, affecting approximately 400,000 individuals in the United States and 2.1 million worldwide. There is no cure for MS and the few treatments available, often associated with severe side effects, can only modify the disease course with the goal of reducing the attacks and improve the quality of life. Thus, finding new effective therapies is a to priority. The work of many groups, including ours, has linked MS to the detrimental effects of soluble TNF (solTNF) and TNFR1, while transmembrane TNF (tmTNF) is beneficial. On this basis, primary objective of the proposed research is to investigate whether tmTNF-TNFR2 signaling in microglia contributes to tmTNF protective effect in EAE. Our studies will be highly relevant in advancing the general knowledge on the role of TNF in EAE and in the development of a possible new therapeutic intervention for MS. Indeed, the selective solTNF inhibitor XPro1595, which has been instrumental to our studies and is one of the key experimental tools in this proposal, has been approved by the FDA for rheumatoid arthritis clinical trials and is now undergoing pre-clinical evaluations for MS clinical trials. We believe our studies will provide further support for the translation of XPro1595, or other solTNF inhibitors, into MS therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS084303-01A1
Application #
8702441
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Utz, Ursula
Project Start
2014-03-01
Project End
2016-02-21
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$226,238
Indirect Cost
$76,238
Name
University of Miami School of Medicine
Department
None
Type
Organized Research Units
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146